We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Cryoablation Shows Potential as Alternative to Partial Nephrectomy

By MedImaging International staff writers
Posted on 04 Jan 2017
Print article
Image: New research suggests cryoablation could be a safe and effective option for some patients with renal cell carcinoma (Photo courtesy of Healthtap).
Image: New research suggests cryoablation could be a safe and effective option for some patients with renal cell carcinoma (Photo courtesy of Healthtap).
Researchers from the US have presented the results of a study that suggest that CT or MRI image-guided percutaneous cryoablation could be an effective and safe first-line therapy to treat patients with T1 renal cell carcinoma.

While the current standard treatment for T1 renal cell carcinoma is partial nephrectomy, image-guided cryoablation has been used in the past 15 to 20 years as a very good alternative treatment.

The results of the study were presented at the annual Radiological Society of North America (RSNA 2016) meeting, by researchers from the Brigham & Women's Hospital (BWH; Boston, MA, USA). Image-guided cryoablation is much less invasive than partial nephrectomy and only requires the insertion of one or several needles into the tumor, and the subsequent freezing of the tumor.

The study included 285 patients with solitary renal cell carcinomas who were treated with percutaneous image-guided cryoablation. Tumors were ablated using between one and seven cryoprobes, and image guidance was provided using Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans.

The results showed a success rate (no tumor recurrence) of 97.8% for the cryoablation treatments. The overall success rate was 99% if patients underwent a second ablation because of disease recurrence. The overall survival rates after five years and 10 years were 90% and 79% respectively. The disease-specific survival rate was 98%, and 10-year cancer-free survival was 94%.

Co-author of the study, Kemal Tuncali, MD, from the BWH, said, "A number of studies have been published looking at image-guided ablation or radio frequency ablation of kidney tumors, but all have been relatively small series. The advantage of our study is that it included a larger patient population and included intermediate and long-term follow ups."

Related Links:
Brigham & Women's Hospital

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Laptop Ultrasound Scanner
PL-3018
Compact C-Arm with FPD
Arcovis DRF-C R21
New
Portable X-Ray Unit
AJEX240H

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.